Method of treating and diagnosing sleep disordered breathing and means for carrying out the method

• US 20040082519A1
• Filed: 12/12/2003
• Published: 04/29/2004
• Est. Priority Date: 02/24/2000
• Status: Active Grant

• Current Assignee: Jan Hedner, Kaj Stenlof, Lars Sjostrom, Ludger Grote
• Original Assignee: Jan Hedner, Kaj Stenlof, Lars Sjostrom, Ludger Grote
• Inventors: Hedner, Jan, Grote, Ludger, Sjöström, Kars, Stenlöf, Kaj
• Granted Patent: US 7,981,443 B2
• Time in Patent Office: Days
• US Class Current: 514/23
• CPC Class Codes: A61K 31/357 having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• CPC Class Codes: A61K 9/7023 Transdermal patches and similar drug-containing composite devices, e.g. cataplasms galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/16 Central respiratory analeptics

Abstract

A method for treating snoring, sleep apnoea and other forms of sleep disordered breathing comprises administration to a patient of a therapeutically effective amount of topiramate over an appropriate period of time, such as a period substantially coniciding with the sleep period of a patient. A useful route of administration is per os. Also disclosed is the use of topiramate for the diagnosis of snoring, sleep apnoea and other forms of sleep disordered breathing.

Claims

1. A method for treating sleep disordered breathing including sleep apnoea comprising administration to a patient a therapeutically effective dose of topiramate.

2. The method of claim 1, wherein said therapeutically effective dose is effective during a substantial portion of a single sleep period.

3. The method of claim 2, wherein said substantial portion is 50% or more.

4. The method of claim 2, wherein said substantial portion is 80% or more.

5. The method of any of claims 2 to 4, wherein said single sleep period is from one to eight hours.

6. The method of any of claims 1 to 5, wherein the administration is peroral.

7. The method of claim 6, wherein the therapeutically active dose is released from a composition for controlled release.

8. The method of claim 7, wherein from 50% to 100% of the therapeutically effective dose is released within a period of three hours from administration.

9. The method of claim 7, wherein from 80% to 100% of the therapeutically effective dose is released within a period of five hours from administration.

10. The method of any of claims 1-9, wherein said therapeutically effective dose is from 10 to 1000 mg.

11. Use of topiramate for the manufacture of a medicament or the treatment of sleep disordered breathing including sleep apnea.

12. The use of claim 11, wherein the medicament is intended for peroral administration.

13. The use of claim 11 or 12, wherein the medicament is designed to release from 50% to 100% of topiramate within a period of three hours from administration.

14. The use of claim 11 or 12, wherein the medicament is designed to release from 80% to 100% of topiramate within a period of five hours from administration.

15. The use of claim 11, wherein the medicament is intended for transdermal administration.

16. The use of claim 11, wherein the medicament is intended for transmucosal administration.

17. A protective patch comprising topiramate in an amount therapeutically effective in the treatment of sleep disordered breathing including sleep apnea and a pharmaceutically acceptable carrier for transdermal or transmucosal administration.

18. Use of topiramate for the manufacture of a diagnostic device, kit or composition for the diagnosis of sleep disordered breathing.